Postoperative adjuvant therapy for stage IB non-small-cell lung cancer (Q43681814)

25 November 2017

title

Postoperative adjuvant therapy for stage IB non-small-cell lung cancer (English)

1 reference

25 November 2017

Mineo TC

1 reference

25 November 2017

Ambrogi V

series ordinal

1 reference

25 November 2017

Corsaro V

series ordinal

1 reference

25 November 2017

Roselli M

series ordinal

1 reference

25 November 2017

publication date

1 August 2001

1 reference

European Journal of Cardio-Thoracic Surgery

25 November 2017

published in

1 reference

25 November 2017

1 reference

25 November 2017

1 reference

25 November 2017

page(s)

378-384

1 reference

Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJS

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Implications of Staging in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: still controversial after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

Incidence of local recurrence and second primary tumors in resected stage I lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

7 January 2021

Micrometastatic p53-positive cells in the lymph nodes of non-small-cell lung cancer: Prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

7 January 2021

Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

7 January 2021

Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

7 January 2021

Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

7 January 2021

Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

7 January 2021

Lung cancer staging and treatment in multidisciplinary trials: Cancer and Leukemia Group B cooperative group approach. Thoracic Surgeons of CALGB

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2801%2900779-5

7 January 2021

10.1016/S1010-7940(01)00779-5

Identifiers

DOI

1 reference

25 November 2017

1 reference